https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14771 Wed 11 Apr 2018 16:01:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14312 Wed 11 Apr 2018 15:21:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14800 = 20 news reports (total 2350 stories); nine of these cost more than AU$10,000 per course or year of treatment. For these 18 medicines, 31% of stories appeared in the six months prior to the PBAC meeting, 14% in the meeting month and 33% in the six months post-meeting. 38% of the stories had >= 3 medicine mentions, 37% referred to the PBS, 24% to cost to the patient, and 9% cost to Government. There was active patient lobby group campaigning in support of listing of infliximab and pemetrexed; the stories for ADHD were often more negative, referring to the dangers of the medicines and sometimes questioning the appropriateness of treatment and public subsidy. There was little discussion of the PBAC's evidence-based decision-making processes. Conclusions: While there was no general trend to increased news reporting associated with PBAC meetings, some drugs did attract media attention. With more new and expensive drugs, decisions on public funding will become increasingly difficult. The media have an important role in enhancing public understanding of the issues around resource allocation. Specialist journalists, guidelines and checklists may help reporting.]]> Wed 11 Apr 2018 11:22:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:533 Thu 25 Jul 2013 09:10:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28262 Thu 13 Jan 2022 10:30:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7012 Sat 24 Mar 2018 08:38:05 AEDT ]]>